News | Contrast Media | November 04, 2019

GE Healthcare announces FDA approval of macrocyclic MRI contrast agent Clariscan

The MRI contrast agent Clariscan (gadoterate meglumine) is now FDA approved for injection for intravenous use

The U.S. Food and Drug Administration (FDA) has approved Clariscan, a macrocyclic, ionic, gadolinium-based, magnetic resonance imaging (MRI) contrast agent, expanding the GE Healthcare portfolio

November 4, 2019 – The U.S. Food and Drug Administration (FDA) has approved Clariscan, a macrocyclic, ionic, gadolinium-based, magnetic resonance imaging (MRI) contrast agent, expanding the GE Healthcare portfolio for U.S. patients and radiologists. Clariscan is a gadolinium-based contrast agent indicated for intravenous use with MRI in brain (intracranial), spine and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Clariscan has been approved in more than 55 countries globally and has had more than four million patient doses shipped in those countries. It is the latest in a growing range of imaging agents available in the U.S. from GE Healthcare. For more than 40 years, GE agents have been routinely used across MRI, X-ray/ computed tomography (CT) and ultrasound to enhance the image and support diagnosis.

“Demand for contrast media has significantly increased over the past decade. The introduction of Clariscan increases our clinical offering for U.S. radiologists, enhancing visualization to provide better patient care. Our customers rely on our high-quality products, first-rate supply network, and surrounding services to support their day-to-day work,” explained Kevin O’Neill, president and CEO Pharmaceutical Diagnostics at GE Healthcare.

“The FDA’s approval of this macrocyclic MR agent adds to the range of contrast media options available here in the U.S. and as radiologists we welcome this broader choice,” said Lawrence N Tanenbaum, M.D., FACR

GE Healthcare offers diagnostic imaging agents used in approximately 90 million procedures per year globally, equivalent to three patients every second. In the U.S., GE Healthcare has a strong record of innovation in new contrast media products and indications, with recent FDA approvals for Omnipaque (iohexol) in CT of the abdomen and for Visipaque (iodixanol) in coronary CT angiography. GE Healthcare has invested $240 million in its global manufacturing and supply network over the past five years to deliver imaging agents to hospitals and pharmacies globally.

Clariscan is manufactured in Norway using a proprietary manufacturing process. As with all GE Healthcare contrast media products, all stages of manufacturing, from development of the active pharmaceutical ingredient (API) to finished product, are managed entirely by GE Healthcare. Clariscan is available in single dose vials of 10, 15 and 20 mL. The packaging contains a 2D data matrix (barcode) on every Clariscan pack, which conveys key information, including national drug code number, individual lot number, and expiration date. This information can be easily scanned and uploaded onto electronic medical systems, helping to reduce the risk of manual data entry errors and helping workflow efficiencies at medical centers. 

For more information: https://corporate.gehealthcare.com/ 

Related content:

VIDEO: Managing Gadolinium Safety

Strategies to Lower CT Contrast Dose and Track Usage

Nurse Injured in MRI Accident at Swedish Hospital

Indian Man Killed in MRI Accident

Related Content

Sponsored Content | Videos | Mammography | January 24, 2020
Imaging Technology News Contributing Editor Greg Freiherr interviewed...
Iodine-based CT contrast ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs.
News | Radiology Imaging | January 22, 2020
January 22, 2020 — The risk of administering modern...
Medical imaging technology company Oxipit announced partnership with Swiss medical distribution company Healthcare Konnect to bring ChestEye AI imaging suite to healthcare institutions in Nigeria
News | Artificial Intelligence | January 22, 2020
January 22, 2020 — Medical imaging technology company Oxipit ann
Sponsored Content | Videos | Enterprise Imaging | January 20, 2020
GE Healthcare's iCenter is a cloud-based management software that provides 24/7 visibility to customers' visual and o
This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.   #RSNA #

This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.

Feature | RSNA | January 20, 2020 | Dave Fornell, Editor
Here are images of some of the newest new medical imaging technologies displayed on the expo floor at the ...
Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
January 17, 2020 — Bracco Diagnostics Inc., the U.
Carestream’s X-ray digital tomosynthesis functionality creates three-dimensional datasets from digital radiography (DR) that can be scrolled through similar to computed tomography (CT) imaging. It received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in January 2020. Digital tomosynthesis uses a single sweep of X-ray exposures and streamlines operator workflow by separating the process of DT exposure acquisition from image volume formation.
News | Digital Radiography (DR) | January 15, 2020
January 15, 2020 — Carestream’s X-ray digital tomosynthesis (DT) functionality, which creates three-dimensional datas
Imaging Technology News (ITN) has been acquired by Wainscot Media
News | Imaging Technology News - ITN | January 14, 2020
January 14, 2020 — Park Ridge, N.J.-based publisher Wainscot Medi...
Videos | RSNA | January 13, 2020
ITN Editor Dave Fornell takes a tour of some of the most innovative new medical imaging technologies displayed on the